These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23633620)

  • 1. Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma.
    Cha H; Yoon HI; Lee IJ; Koom WS; Han KH; Seong J
    J Radiat Res; 2013 Nov; 54(6):1069-77. PubMed ID: 23633620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study.
    Kim JK; Kim JW; Lee IJ; Joo SM; Lee KH; Cho ES; Yu JS; Jeon TJ; Kim Y; Lee JI; Lee KS
    Radiat Oncol; 2017 Aug; 12(1):133. PubMed ID: 28810886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma.
    Lee MH; Kim SU; Kim DY; Ahn SH; Choi EH; Lee KH; Lee DY; Seong J; Han KH; Chon CY; Park JY
    J Gastroenterol Hepatol; 2012 Feb; 27(2):313-22. PubMed ID: 21793906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy.
    Han DH; Joo DJ; Kim MS; Choi GH; Choi JS; Park YN; Seong J; Han KH; Kim SI
    Yonsei Med J; 2016 Sep; 57(5):1276-81. PubMed ID: 27401662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
    Kim BK; Ahn SH; Seong JS; Park JY; Kim DY; Kim JK; Lee DY; Lee KH; Han KH
    Liver Int; 2011 Mar; 31(3):369-76. PubMed ID: 21083802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma.
    Lee IJ; Kim JW; Han KH; Kim JK; Kim KS; Choi JS; Park YN; Seong J
    Yonsei Med J; 2014 Nov; 55(6):1489-97. PubMed ID: 25323884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion.
    Onishi H; Nouso K; Nakamura S; Katsui K; Wada N; Morimoto Y; Miyahara K; Takeuchi Y; Kuwaki K; Yasunaka T; Miyake Y; Shiraha H; Takaki A; Kobayashi Y; Sakaguchi K; Kanazawa S; Yamamoto K
    Hepatol Int; 2015 Jan; 9(1):105-12. PubMed ID: 25788384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
    Han S; Choi HJ; Beom SH; Kim HR; Lee H; Lee JS; Lee HW; Park JY; Kim SU; Kim DY; Ahn SH; Han KH; Seong J; Won JY; Kim BK
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3123-3133. PubMed ID: 33893539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Chong JU; Choi GH; Han DH; Kim KS; Seong J; Han KH; Choi JS
    Ann Surg Oncol; 2018 Oct; 25(11):3308-3315. PubMed ID: 30083834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy.
    Lee HS; Choi GH; Choi JS; Kim KS; Han KH; Seong J; Ahn SH; Kim DY; Park JY; Kim SU; Kim BK
    Ann Surg Oncol; 2014 Oct; 21(11):3646-53. PubMed ID: 24916746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
    Kodama K; Kawaoka T; Aikata H; Uchikawa S; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Kimura T; Nagata Y; Chayama K
    Oncology; 2018; 94(4):215-222. PubMed ID: 29428943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Song JE; Jung KS; Kim DY; Song K; Won JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Seong J; Han KH
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):396-406. PubMed ID: 28871990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial.
    Kim BK; Kim DY; Byun HK; Choi HJ; Beom SH; Lee HW; Kim SU; Park JY; Ahn SH; Seong J; Han KH
    Int J Radiat Oncol Biol Phys; 2020 May; 107(1):106-115. PubMed ID: 32084526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Yoon HI; Song KJ; Lee IJ; Kim DY; Han KH; Seong J
    Cancer Res Treat; 2016 Jan; 48(1):190-7. PubMed ID: 25761480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of ¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study.
    Lee JW; Oh JK; Chung YA; Na SJ; Hyun SH; Hong IK; Eo JS; Song BI; Kim TS; Kim DY; Kim SU; Moon DH; Lee JD; Yun M
    J Nucl Med; 2016 Apr; 57(4):509-16. PubMed ID: 26742711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma.
    Kim BK; Kang WJ; Kim JK; Seong J; Park JY; Kim DY; Ahn SH; Lee DY; Lee KH; Lee JD; Han KH
    Cancer; 2011 Oct; 117(20):4779-87. PubMed ID: 21469082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy.
    Choi Y; Kim JW; Cha H; Han KH; Seong J
    J Radiat Res; 2014 Jan; 55(1):113-20. PubMed ID: 23772086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy.
    Cha H; Lee EJ; Seong J
    World J Gastroenterol; 2017 Mar; 23(11):2077-2085. PubMed ID: 28373775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis.
    Park MS; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Chon CY; Seong J
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):165-73. PubMed ID: 23079897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.